Urinary prostaglandin D 2 metabolite appears to be a useful biomarker for evaluating the status of egg oral immunotherapy in children
Urinary prostaglandin D 2 metabolite appears to be a useful biomarker for evaluating the status of egg oral immunotherapy in children
复制标题
尿前列腺素 D 2 代谢物似乎是评估儿童鸡蛋口服免疫治疗状态的有用生物标志物
DOI：
10.1016/j.jaip.2021.06.040
复制
发表时间：
2021
期刊：
影响因子：
--
通讯作者：
Yukihiro Ohya
中科院分区：
文献类型：
--
作者：
Shinichiro Inagaki;Tatsuro Nakamura;Osamu Natsume;Kiwako Yamamoto-Hanada;Tatsuki Fukuie;Masami Narita;Tatsuo Shimosawa;Takahisa Murata;Yukihiro Ohya
本研究首次证明尿前列腺素D2代谢产物水平可作为一种非侵入性生物标志物，用于评估食物过敏儿童口服免疫治疗期间脱敏状态。食物过敏（FA）是一个日益普遍的全球性健康问题。1以前，对FA的唯一管理是避免食物过敏原。然而，口服免疫疗法（OIT）作为FA的潜在治疗选择越来越受欢迎。2，3最近，一种用于花生OIT的产品Palforzia（Aimmune Therapeutics，布里斯班，加利福尼亚州）被美国食品和药物管理局批准用于4至17岁的儿童。OIT涉及每天持续摄入逐渐增加剂量的食物过敏原，这可以在FA患者中诱导脱敏或耐受状态，维持期从数月到数年不等。4在许多试验中，在维持期结束时进行了口服食物激发（OFC），以评估OIT的有效性。4据报道，21%至100%的患者在完成OIT后获得脱敏。4尽管OFC对于确认脱敏或耐受的获得是必要的，但OFC通常可能伴有严重的过敏反应。因此，必须确定能够监测脱敏和OIT疗效的生物标志物，以确保在适当的时间进行OFC。
This is the first study to demonstrate that the level of the urinary prostaglandin D 2 metabolite can be used as a noninvasive biomarker to assess the state of desensitization during oral immunotherapy in children with food allergies.Food allergy (FA) is an increasingly prevalent global health problem. 1 Previously, the only management for FA was the avoidance of food allergens. However, oral immunotherapy (OIT) has become increasingly popular as a potential treatment option for FA. 2, 3 Recently, a product for peanut OIT, Palforzia (Aimmune Therapeutics, Brisbane, Calif), was approved by the US Food and Drug Administration for use in children aged 4 to 17 years. OIT involves the continued daily consumption of a progressively escalating dose of food allergen, which can induce a state of desensitization or tolerance in patients with FA after a maintenance period ranging from months to years. 4 In numerous trials, oral food challenges (OFCs) have been performed at the end of the maintenance period to evaluate the effectiveness of OIT. 4 Reportedly, 21% to 100% of patients acquire desensitization after completing OIT. 4 Although OFCs are necessary to confirm the acquisition of desensitization or tolerance, OFCs may often be accompanied by severe allergic reactions. Therefore, biomarkers capable of monitoring desensitization and OIT efficacy must be identified to ensure that OFCs are performed at appropriate times.